A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
Phase 3 study of safety and efficacy of Daratumumab in combination with other drugs in treating AL Amyloidosis
Sponsor: Janssen
Enrolling: Male and Female Patients
IRB Number: AAAR4157
U.S. Govt. ID: NCT03201965
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if daratumumab when given with three other drugs cyclophosphamide, bortezomib (VELCADE) and dexamethasone is useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis). The study will look at what happens (both good and bad) when daratumumab is given with these three drugs compared to just giving those three drugs alone. The safety of daratumumab when given with cyclophosphamide, bortezomib and dexamethasone (CyBorD) will also be studied.
This study is closed
Divaya Bhutani, MD
Do You Qualify?
Do you have amyloidosis? Yes No
Do you have one or more organs impacted by Amyloidosis? Yes No
Have you received prior therapy for AL Amyloidosis or Multiple Myeloma? Yes No
Have you been diagnosed with symptomatic multiple myeloma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator